Skip to main content
Clinical Trials/NCT05881655
NCT05881655
Recruiting
Not Applicable

A Prospective Clinical Trial on Slow Myopia Progression With Two Different Irradiance Light at Baseline and Dynamic Changes at Follow-up

Beijing Airdoc Technology Co., Ltd.1 site in 1 country75 target enrollmentMay 20, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myopia, Progressive
Sponsor
Beijing Airdoc Technology Co., Ltd.
Enrollment
75
Locations
1
Primary Endpoint
Mean Change of Ocular Axial length elongation at follow-up from Baseline (mm)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

It is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. Study Groups with two different powers of 0.6 mW and 1.2 mW at wavelength of 650nm. The control group is to wear the same brand and design spectalces as those two study groups. In addition, the progression of myopia is usually accompanied by the changes in a variety of ocular parameters, such as refractive error, reduced submacular choroidal thickness, and prolonged length of the ocular axis length.The goal is to test which power (1.2mW and 0.6mW) is better in myopic children for 3 month's follow-up and also to test how to get better result with the increaing or decreasing lighting power for the total 6 month follow-up results .

Detailed Description

It is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. Each group has 25 myopic children. Study Groups with two different powers of 0.6 mW and 1.2 mW at wavelength of 650nm are randomized to be allocated into the 3 groups. The control group is to wear the same brand and design spectalces as those two study groups. In addition, the progression of myopia is usually accompanied by the changes in a variety of ocular parameters, such as refractive error, reduced submacular choroidal thickness, and prolonged length of the ocular axis length. All groups will be wearing a special lens named by Stellest with high aspherical lens design.

Registry
clinicaltrials.gov
Start Date
May 20, 2023
End Date
December 30, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 6\~12 years old
  • Refractive Error of Myopia within -0.50 D\~-5.00 D, Anisometropia less or equal to 2.00D, The best corrected vision acuity is better or equal to 0.8 (decimal record).
  • Written consent formed with supervisions and children with 6 month follow-up.

Exclusion Criteria

  • Photophobia or allergy to any cycloplegic eyedrops (such as tropcaine, cyclopentolate).
  • Lesions in fundus or any part of eyeball with abnormal corrected vision such as keratoconus.
  • Strabisumus with angles large or equal to 5 prism dioper.
  • With other myopia control device such as atropine, Orthokeratology, Misight lens or other myopia control device.

Outcomes

Primary Outcomes

Mean Change of Ocular Axial length elongation at follow-up from Baseline (mm)

Time Frame: 6-month

Measured with IOLmaster 500 or Lenstar at follow-up from baseline

Secondary Outcomes

  • Change of Fundus(6-month)
  • Mean Change of Choroidal Thickness (um)(6-month)
  • Mean Change of Refractive Error at follow-up from Baseline (mm)(6-month)

Study Sites (1)

Loading locations...

Similar Trials